New PET scans reveal how Immune-Boosting drugs target tumors
NCT ID NCT05068102
First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times
Summary
This study is for adults with advanced head and neck, lung, or skin cancer who have not responded to prior treatments. Researchers use special PET scans to see how two experimental drugs (BI 765063 and BI 770371) travel through the body and reach tumors. Participants receive one of these drugs along with another immune-boosting medicine (ezabenlimab) every three weeks. The goal is to understand drug distribution, not to cure the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, SQUAMOUS CELL OF HEAD AND NECK (HNSCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
VU University Medical Center
Amsterdam, 1081HV, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can new drug cocktails reawaken the immune system against melanoma?
- Could a Six-Month exercise and diet plan shield muscle during melanoma treatment?
- Quitting before the knife: which Stop-Smoking aid works best for cancer patients?
- Can a One-Two punch of immune boosters revive cancer treatment?
- Can a modified herpes virus turn the tide against advanced cancer?
- Can your genes predict your melanoma risk?